Higher serum lipocalin 2 is associated with post-stroke depression at discharge.
Acute ischemic stroke
Inflammatory markers
LCN2
Lipocalin 2
Post-stroke depression
Journal
BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555
Informations de publication
Date de publication:
05 Aug 2023
05 Aug 2023
Historique:
received:
22
04
2023
accepted:
05
07
2023
medline:
7
8
2023
pubmed:
6
8
2023
entrez:
5
8
2023
Statut:
epublish
Résumé
Post-stroke depression (PSD), as one of the common complications after stroke, seriously affects the physical and mental health and functional prognosis of patients. Previous studies have shown that the increase of inflammatory mediators is associated with the occurrence of PSD. Lipocalin 2 (LCN2), as an acute phase protein, is involved in the development of acute ischemic stroke (AIS), and its expression is up-regulated in patients with depression, suggesting that there is a potential correlation between serum LCN2 and depression. The aim of this study was to explore the relationship between serum LCN2 at admission and PSD at discharge. A total of 358 AIS patients were retrospectively included. All patients had fasting venous blood taken within 24 h of admission to detect serum LCN2. The patients were evaluated by 17-item Hamilton Depression Scale (HAMD) before discharge. Patients with HAMD score > 7 were diagnosed with PSD. The correlation between serum LCN2 and PSD was tested using binary logistic regression analysis. In our study, 92 (25.7%) patients were diagnosed with PSD at discharge. According to the serum LCN2 value, the patients were divided into three layers (Tertile1 ≤ 105.24ng/ml; Tertile2: 105.24-140.12ng/ml; Tertile3 ≥ 140.12ng/ml), with T1 layer (the lowest levels) as a reference, after adjusting for multiple potential confounding factors, T3 layer (the highest levels) was independently associated with the occurrence of PSD (odds ratio [OR] = 2.639, 95% confidence interval [CI]: 1.317-5.287, P = 0.006). Similar results were found when the serum LCN2 was analyzed as a continuous variable. The optimal cut-off value of serum LCN2 at admission to predict PSD at discharge was 117.60ng/ml, at this threshold, the sensitivity was 77.2%, and the specificity was 53.4%. High serum LCN2 levels at admission are an independent risk factor for PSD in patients with AIS at discharge.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Post-stroke depression (PSD), as one of the common complications after stroke, seriously affects the physical and mental health and functional prognosis of patients. Previous studies have shown that the increase of inflammatory mediators is associated with the occurrence of PSD. Lipocalin 2 (LCN2), as an acute phase protein, is involved in the development of acute ischemic stroke (AIS), and its expression is up-regulated in patients with depression, suggesting that there is a potential correlation between serum LCN2 and depression. The aim of this study was to explore the relationship between serum LCN2 at admission and PSD at discharge.
METHODS
METHODS
A total of 358 AIS patients were retrospectively included. All patients had fasting venous blood taken within 24 h of admission to detect serum LCN2. The patients were evaluated by 17-item Hamilton Depression Scale (HAMD) before discharge. Patients with HAMD score > 7 were diagnosed with PSD. The correlation between serum LCN2 and PSD was tested using binary logistic regression analysis.
RESULTS
RESULTS
In our study, 92 (25.7%) patients were diagnosed with PSD at discharge. According to the serum LCN2 value, the patients were divided into three layers (Tertile1 ≤ 105.24ng/ml; Tertile2: 105.24-140.12ng/ml; Tertile3 ≥ 140.12ng/ml), with T1 layer (the lowest levels) as a reference, after adjusting for multiple potential confounding factors, T3 layer (the highest levels) was independently associated with the occurrence of PSD (odds ratio [OR] = 2.639, 95% confidence interval [CI]: 1.317-5.287, P = 0.006). Similar results were found when the serum LCN2 was analyzed as a continuous variable. The optimal cut-off value of serum LCN2 at admission to predict PSD at discharge was 117.60ng/ml, at this threshold, the sensitivity was 77.2%, and the specificity was 53.4%.
CONCLUSIONS
CONCLUSIONS
High serum LCN2 levels at admission are an independent risk factor for PSD in patients with AIS at discharge.
Identifiants
pubmed: 37543589
doi: 10.1186/s12883-023-03319-y
pii: 10.1186/s12883-023-03319-y
pmc: PMC10403916
doi:
Substances chimiques
Lipocalin-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
294Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Cell Mol Med. 2012 Sep;16(9):1961-9
pubmed: 22348642
J Clin Lab Anal. 2022 Jul;36(7):e24526
pubmed: 35657334
Stroke. 2017 Jul;48(7):2007-2012
pubmed: 28626052
Psychoneuroendocrinology. 2014 Oct;48:169-77
pubmed: 25019974
Ageing Res Rev. 2021 Sep;70:101414
pubmed: 34325073
Lancet Neurol. 2019 Apr;18(4):394-405
pubmed: 30878104
Front Psychiatry. 2021 Jun 25;12:556981
pubmed: 34248685
Cerebrovasc Dis. 2000 Mar-Apr;10(2):97-101
pubmed: 10686447
Stroke. 2023 May;54(5):1289-1299
pubmed: 37026458
J Psychosom Res. 2013 Nov;75(5):444-50
pubmed: 24182633
Psychoneuroendocrinology. 2016 Oct;72:156-60
pubmed: 27428088
Front Aging Neurosci. 2021 Dec 13;13:798335
pubmed: 34966272
Mol Neurobiol. 2017 Sep;54(7):4847-4865
pubmed: 27510505
Neurosci Biobehav Rev. 2022 Mar;134:104309
pubmed: 34416242
Gen Hosp Psychiatry. 2020 Sep - Oct;66:70-80
pubmed: 32717644
Brain Sci. 2022 Aug 03;12(8):
pubmed: 36009095
Brain Behav Immun. 2021 Oct;97:102-118
pubmed: 34245812
PLoS One. 2013 Jun 17;8(6):e66607
pubmed: 23799122
Neurosci Biobehav Rev. 2015 Feb;49:135-56
pubmed: 25511817
Immunol Res. 2023 Jun;71(3):287-313
pubmed: 36529828
Am J Geriatr Psychiatry. 2017 Dec;25(12):1300-1308
pubmed: 28844626
J Neuropsychiatry Clin Neurosci. 2013 Fall;25(4):255-63
pubmed: 24247852
Mol Biol Rep. 2020 Mar;47(3):2327-2346
pubmed: 31970626
J Physiother. 2014 Mar;60(1):61
pubmed: 24856948
Neurobiol Dis. 2023 Apr;179:106044
pubmed: 36804285
Trends Endocrinol Metab. 2017 May;28(5):388-397
pubmed: 28214071
PeerJ. 2023 Jan 10;11:e14440
pubmed: 36643631
Lancet. 2005 Apr 2-8;365(9466):1231-8
pubmed: 15811456
J Neurol Sci. 2011 Jun 15;305(1-2):28-33
pubmed: 21463871
J Neurol Neurosurg Psychiatry. 2017 Jun;88(6):498-504
pubmed: 28331011
Nat Commun. 2021 Apr 6;12(1):2057
pubmed: 33824339
Front Immunol. 2022 Sep 26;13:1000631
pubmed: 36225923
JAMA. 2017 Apr 18;317(15):1517
pubmed: 28418490
Stroke. 2011 Apr;42(4):1146-51
pubmed: 21372310
PLoS One. 2016 May 06;11(5):e0154797
pubmed: 27152948
J Cell Mol Med. 2015 Jul;19(7):1637-45
pubmed: 25702801
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
Nature. 2017 Mar 16;543(7645):385-390
pubmed: 28273060
J Biol Chem. 1993 May 15;268(14):10425-32
pubmed: 7683678
Stroke. 1996 Oct;27(10):1734-8
pubmed: 8841320
Int J Mol Sci. 2020 Aug 29;21(17):
pubmed: 32872405
Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18436-41
pubmed: 21969573
Brain Behav Immun. 2014 May;38:59-65
pubmed: 24407045
J Am Soc Nephrol. 2006 Oct;17(10):2937-44
pubmed: 16988059
JAMA Psychiatry. 2016 Oct 01;73(10):1032-1040
pubmed: 27603000